Head to head
P21 vs Semax
Two compounds that are more often stacked than compared — the side-by-side data, and what actually separates them.
Verdict
Usually stacked — and only Semax has human trial data
What you are actually choosing between
Before anything else: the dataset lists P21 and Semax in each other's stacks. They are run together more often than they are chosen between, so if you came here for a winner, the first honest answer is that this may not be an either/or.
Both are classed here as nootropics, so this is a within-class choice: the mechanism is broadly shared and what separates them is kinetics, route, and how much has actually been tested.
The overlap is focus and cognition and neuroprotection. On this site's goal weighting — an editorial priority score, not a measure of effect size — P21 rates 5/5 for focus and cognition and Semax rates 5/5.
The evidence
This is the part that decides most of it. Semax has approval from a regulator somewhere, though not a current FDA or EMA label — a registered Russian medicine; Western trial data is essentially absent. P21 has animal and cell data only, and no controlled human dosing trials — there is essentially no human data at all. That gap is the headline, and it is a statement about the literature rather than a promise about you: a compound with trial data can still do nothing for your case, and one without it is unproven rather than disproven.
How they differ in practice
P21 is a subcutaneous injection and a nasal spray; Semax is a nasal spray and a subcutaneous injection. Neither one forces you onto a needle.
No half-life is published for either compound in this dataset. That absence is itself information: it means the pharmacokinetics have not been characterized well enough to quote, so both dosing schedules — once daily for P21, twice daily for Semax — are convention.
Risk and difficulty
Semax is rated intermediate here and P21 advanced. That rating is about how much can go wrong in handling, dosing and monitoring, not about how well either works.
Source notes
What the evidence actually says
Verbatim, so you can check the verdict above against what it was built from.
P21
THERE IS ESSENTIALLY NO HUMAN DATA ON P21. It is a small adamantylated tetrapeptide derivative (Ac-DGGL-amide) of an 11-residue active region of ciliary neurotrophic factor, designed to be orally available and blood-brain-barrier permeable. The entire evidence base is preclinical: transgenic and aged rodent models of Alzheimer disease and Down syndrome, reporting increased neurogenesis and BDNF signaling and reduced tau hyperphosphorylation, from the group that developed it at the New York State Institute for Basic Research. No human trial has been published, no human pharmacokinetic or toxicology data exists, and no approved product exists anywhere. Rodent work dosed it orally or subcutaneously; the subcutaneous and intranasal routes listed here reflect how unregulated users actually take it. The range given is deliberately narrow and conservative and is extrapolated from that practice, NOT from any dose-finding study - treat it as a description, not a recommendation. It is frequently confused with the unrelated cell-cycle protein p21 (CDKN1A); they are not the same thing.
Semax
A synthetic heptapeptide: the ACTH(4-7) fragment extended with a Pro-Gly-Pro tail that blocks rapid enzymatic breakdown. It has no ACTH-like hormonal activity. Semax is a registered medicine in Russia and is given intranasally as a 0.1% or 1% solution; it is NOT approved in the US or EU and Western trial data is essentially absent, so the human evidence base is Russian-language and mostly from a small number of groups. Route matters here: it is an intranasal drug, not an injectable, and the nose-to-brain path is the whole point of the formulation. Russian dosing convention for cognitive and asthenic indications is roughly 200-2000 mcg per day split across two or three administrations (a few drops or sprays per nostril); the per-dose range listed here reflects that split, not the daily total. Much higher doses (around 12 mg/day of the 1% solution) have been used in acute ischaemic stroke under hospital supervision and are outside the scope of self-directed use. Plasma half-life is measured in minutes, so no meaningful hourly figure is listed; reported CNS effects outlast plasma presence.
Side by side
The numbers
| Attribute | P21 | Semax |
|---|---|---|
| Class | Nootropic | Nootropic |
| Routes | Subcutaneous, Intranasal | Intranasal, Subcutaneous |
| Dose range | 250 mcg–1 mg (typical 500 mcg) | 100 mcg–1 mg (typical 300 mcg) |
| Frequency | Once daily | Twice daily |
| Half-life | Not characterized | Not characterized |
| Cycle length | 4 weeks | 4 weeks |
| Experience | Advanced | Intermediate |
| Evidence | Animal / cell data only | Approved elsewhere |
| Contraindications |
|
|
| Side effects |
|
|
Goals
Where they overlap, and where they do not
| Goal | P21 | Semax |
|---|---|---|
| focus and cognition | P21: 5/5 | Semax: 5/5 |
| neuroprotection | P21: 5/5 | Semax: 4/5 |
| longevityone only | P21: 2/5 | Semax: — |
| recovery and sleepone only | P21: — | Semax: 2/5 |
They overlap on 2 goals and diverge on 2. Weights are this site’s editorial priority score out of 5 — how central a goal is to why people use a compound. They are not effect sizes and two 5s do not mean two equal results.
Next
Go deeper
Related
Other comparisons with these two
Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.